{"id":18586,"date":"2023-12-11T00:23:40","date_gmt":"2023-12-10T23:23:40","guid":{"rendered":"http:\/\/mabdesign.fr\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/"},"modified":"2023-12-11T00:25:16","modified_gmt":"2023-12-10T23:25:16","slug":"osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/","title":{"rendered":"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836"},"content":{"rendered":"\n

Lyon, France \u2013 December 5, 2023 \u2013<\/strong> Osivax<\/a>, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that it has received a grant of over USD 1.5M from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). The grant (project number 1R01AI177376) will support preclinical studies evaluating the breadth of protection and immune response induced by the company\u2019s lead, broad-spectrum influenza vaccine candidate, OVX836 against pandemic influenza strains.<\/p>\n\n

The preclinical studies are planned to be conducted at the Infectious Diseases Models for Innovative Therapies (IDMIT) department at the French Alternative Energies and Atomic Energy Commission (CEA) site in Fontenay-aux-Roses, France. The IDMIT is highly specialized in human infectious diseases and has the facilities needed for testing the immunogenicity and efficacy of OVX836 as a vaccine against pandemic influenza strains in preclinical models. To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836.<\/p>\n","protected":false},"author":2,"featured_media":708,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-18586","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-our-members"],"yoast_head":"\nOsivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836 - MabDesign<\/title>\n<meta name=\"description\" content=\"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836 - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-10T23:23:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-10T23:25:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/OSIVAX-logo-e1500545433396.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"51\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ana-Sofia ANTUNES\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ana-Sofia ANTUNES\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/\"},\"author\":{\"name\":\"Ana-Sofia ANTUNES\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/c9d806b58aee7bc48c60b1f93e5b4bdd\"},\"headline\":\"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836\",\"datePublished\":\"2023-12-10T23:23:40+00:00\",\"dateModified\":\"2023-12-10T23:25:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/\"},\"wordCount\":167,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/OSIVAX-logo-e1500545433396.jpg\",\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/\",\"name\":\"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836 - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/OSIVAX-logo-e1500545433396.jpg\",\"datePublished\":\"2023-12-10T23:23:40+00:00\",\"dateModified\":\"2023-12-10T23:25:16+00:00\",\"description\":\"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/OSIVAX-logo-e1500545433396.jpg\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/OSIVAX-logo-e1500545433396.jpg\",\"width\":200,\"height\":51},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/c9d806b58aee7bc48c60b1f93e5b4bdd\",\"name\":\"Ana-Sofia ANTUNES\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/062df62cc2ac391d996212d78eabdba3a6818c6616198c1e68bed19ffba5d93f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/062df62cc2ac391d996212d78eabdba3a6818c6616198c1e68bed19ffba5d93f?s=96&d=mm&r=g\",\"caption\":\"Ana-Sofia ANTUNES\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/ana-sofia-antunesmabdesign-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836 - MabDesign","description":"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/","og_locale":"en_US","og_type":"article","og_title":"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836 - MabDesign","og_description":"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836.","og_url":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/","og_site_name":"MabDesign","article_published_time":"2023-12-10T23:23:40+00:00","article_modified_time":"2023-12-10T23:25:16+00:00","og_image":[{"width":200,"height":51,"url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/OSIVAX-logo-e1500545433396.jpg","type":"image\/jpeg"}],"author":"Ana-Sofia ANTUNES","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Ana-Sofia ANTUNES","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/"},"author":{"name":"Ana-Sofia ANTUNES","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/c9d806b58aee7bc48c60b1f93e5b4bdd"},"headline":"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836","datePublished":"2023-12-10T23:23:40+00:00","dateModified":"2023-12-10T23:25:16+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/"},"wordCount":167,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/OSIVAX-logo-e1500545433396.jpg","articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/","url":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/","name":"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836 - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/OSIVAX-logo-e1500545433396.jpg","datePublished":"2023-12-10T23:23:40+00:00","dateModified":"2023-12-10T23:25:16+00:00","description":"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/OSIVAX-logo-e1500545433396.jpg","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/OSIVAX-logo-e1500545433396.jpg","width":200,"height":51},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/osivax-receives-over-usd-1-5m-grant-from-niaid-to-advance-development-of-broad-spectrum-influenza-vaccine-candidate-ovx836\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/c9d806b58aee7bc48c60b1f93e5b4bdd","name":"Ana-Sofia ANTUNES","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/062df62cc2ac391d996212d78eabdba3a6818c6616198c1e68bed19ffba5d93f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/062df62cc2ac391d996212d78eabdba3a6818c6616198c1e68bed19ffba5d93f?s=96&d=mm&r=g","caption":"Ana-Sofia ANTUNES"},"url":"https:\/\/mabdesign.fr\/en\/author\/ana-sofia-antunesmabdesign-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/18586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=18586"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/18586\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/708"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=18586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=18586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=18586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}